Antitrust Antitrust

Teva, Cephalon fined EUR60.5 million in EU pay-for-delay probe

By Lewis Crofts
  • 26 Nov 2020 06:15
  • 26 Nov 2020 06:51
Pharmaceutical companies Teva and Cephalon must pay 60.5 million euros in fines ($72 million) after the European Commission concluded the companies agreed to delay the market entry of a cheaper drug to treat sleep disorders.
The probe focused on modafinil and sees the EU regulator again sanction conduct where pharmaceutical

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Lewis Crofts


Lewis leads MLex's editorial strategy, content direction, quality and development. He has a reputation for breaking stories and providing analysis on complex legal disputes before regulators and courts around the globe. He has also developed MLex's unrivalled coverage of competition policy, litigation, regulation, Brexit and international investigations.

Discover MLex

Stay on top of global regulatory developments

Latest News